Inclusion Criteria:

- Histologically Confirmed Adenocarcinoma of the Gastroesophageal Junction (AEG I-III)
or Gastric Adenocarcinoma (every T, N+ or T3/T4, Nx, M0)

- Written Informed Consent

- Age ≥ 18 Years

- Expected operability

- ECOG ≤ 2

- Exclusion of Peritoneal Metastasis

- Adequate Hematological, Renal, Cardiac and Hepatic Function

- Effective Contraception

Exclusion Criteria:

- Prior Chemotherapy or Radiotherapy of the Adenocarcinoma of the Gastroesophageal
Junction (AEG I-III) or Gastric Adenocarcinoma

- Not Histologically Confirmed Primary Tumor

- Distant Metastasis, Local Relapse

- Known Hypersensitivity for 5-Fluorouracil, Leucovorin, Oxaliplatin or Docetaxel

- Known Dihydropyrimidin-Dehydrogenase (DPD) - Deficiency

- Peripheral Polyneuropathy ≥ Grade II (NCI-CTCAE, Version 3.0)

- Myocardial Infarction in the last 3 Months, Cardiac Insufficiency Grade II-IV (NYHA)

- Severe Comorbidity or Acute Infections

- Pregnancy or Breast Feeding

- Insufficient Contraception

- Participation in another Clinical Trial (Simultaneously or 30 Days Prior to
Enrollment)

- Malignancy <5 years (except: Carcinoma In Situ of the Cervix Uteri or Adequately
Treated Basalioma of the Skin)

- Lack of Legal Capacity